Cargando…
Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
INTRODUCTION: Prostate cancer is the most common male cancer with one in four developing non-curable metastatic disease. Initial treatment responses to hormonal therapies are transient and further management options lie between (1) further hormone therapy or (2) a non-hormonal approach involving add...
Autores principales: | Clark, Emma, Morton, Miranda, Sharma, Shriya, Fisher, Holly, Howel, Denise, Walker, Jenn, Wood, Ruth, Hancock, Helen, Maier, Rebecca, Marshall, John, Bahl, Amit, Crabb, Simon, Jain, Suneil, Pedley, Ian, Jones, Rob, Staffurth, John, Heer, Rakesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937062/ https://www.ncbi.nlm.nih.gov/pubmed/31857319 http://dx.doi.org/10.1136/bmjopen-2019-034708 |
Ejemplares similares
-
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial
por: Gravestock, Paul, et al.
Publicado: (2023) -
Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015) -
Splice Variants of Androgen Receptor and Prostate Cancer
por: Caffo, Orazio, et al.
Publicado: (2016) -
Regulation of androgen receptor variants in prostate cancer
por: Zhu, Yezi, et al.
Publicado: (2020) -
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)